Mitochondrial myopathy caused by arsenic trioxide therapy.

Abstract

Arsenic trioxide (ATO) has been successfully used as a treatment for acute promyelocytic leukemia (APL) for more than a decade. Here we report a patient with APL who developed a mitochondrial myopathy after treatment with ATO. Three months after ATO therapy withdrawal, the patient was unable to walk without assistance and skeletal muscle studies showed a… (More)
DOI: 10.1182/blood-2011-10-385138

Topics

2 Figures and Tables

Slides referencing similar topics